Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy
Abstract Background Based on the results from the ALFA-0701 study, gemtuzumab ozogamicin (GO) has been approved by the European Medicine Agency and by the Italian Drug Agency for the first line treatment of de novo acute-myeloid leukemia (AML). In this analysis, we assessed the cost-effectiveness of...
保存先:
| 主要な著者: | , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMC
2023-01-01
|
| シリーズ: | BMC Health Services Research |
| 主題: | |
| オンライン･アクセス: | https://doi.org/10.1186/s12913-023-09054-x |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|